SCHEMBL1190585

SCHEMBL1190585

O=C(c1ccc(O[Br+2]([O-])[O-])c(Br)c1)N1CCOc2ccncc21

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 7/20 0.66
SLC22A6 Q4U2R8 1/20 0.66
SLC22A8 Q8TCC7 1/20 0.66
GPBAR1 Q8TDU6 1/20 0.41
POLB P06746 1/20 0.39
KCNH2 Q12809 1/20 0.39
KMT2A Q03164 2/20 0.39
GLA P06280 1/20 0.39
NR3C2 P08235 1/20 0.38
CTSD P07339 1/20 0.35
SCD5 Q86SK9 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
CYP11B2 P19099 1/20 0.33
USP2 O75604 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
TSHR P16473 1/20 0.33
PDE4A P27815 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1191177 0.92 SLC22A12 (0.54) SLC22A12SLC22A6SLC22A8GPBAR1POLB
SCHEMBL1191481 0.89 SLC22A12 (0.56) SLC22A12SLC22A6SLC22A8GPBAR1POLB
SCHEMBL1190777 0.88 SLC22A12 (0.71) SLC22A12SLC22A6SLC22A8GPBAR1POLB
SCHEMBL1190599 0.87 SLC22A12 (0.69) SLC22A12SLC22A6SLC22A8GPBAR1POLB
SCHEMBL1190582 0.84 SLC22A12 (0.71) SLC22A12SLC22A6SLC22A8GPBAR1POLB
SCHEMBL1190488 0.82 SLC22A12 (0.79) SLC22A12SLC22A6SLC22A8GPBAR1POLB
SCHEMBL1191189 0.82 SLC22A12 (0.62) SLC22A12SLC22A6SLC22A8GPBAR1POLB
Epaminurad SCHEMBL1190775 0.81 SLC22A12 (0.89) SLC22A12SLC22A6SLC22A8GPBAR1POLB
SCHEMBL1191389 0.81 GPBAR1 (0.47) SLC22A12SLC22A6SLC22A8GPBAR1POLB
Bromide SCHEMBL1190077 0.81 SLC22A12 (0.77) SLC22A12SLC22A6SLC22A8GPBAR1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2266989-A2 HETEROCYCLIC DERIVATIVES C&c Research Laboratories (KR) 2010-12-29 EP claimed
US-8394792-B2 Heterocyclic derivatives C&C RESEARCH LABORATORIES (KR) 2013-03-12 US disclosed
US-20110028467-A1 HETEROCYCLIC DERIVATIVES C&C RESEARCH LABORATORIES (KR) 2011-02-03 US disclosed
EP-2266989-A2 HETEROCYCLIC DERIVATIVES C&c Research Laboratories (KR) 2010-12-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028467-A1 HETEROCYCLIC DERIVATIVES XDH, NUDT1, UGDH SLC22A12 692/4885SLC22A6 625/4885SLC22A8 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.